Capital CS Group LLC Buys New Stake in Insmed Incorporated (NASDAQ:INSM)

Capital CS Group LLC acquired a new position in Insmed Incorporated (NASDAQ:INSM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,488 shares of the biopharmaceutical company's stock, valued at approximately $586,000. Insmed makes up approximately 0.8% of Capital CS Group LLC's portfolio, making the stock its 24th largest position.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in Insmed in the 3rd quarter valued at about $30,000. GAMMA Investing LLC lifted its holdings in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 224 shares in the last quarter. Exchange Traded Concepts LLC grew its position in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 627 shares during the period. Blue Trust Inc. grew its position in Insmed by 2,348.8% in the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company's stock valued at $131,000 after purchasing an additional 1,879 shares during the period. Finally, JCIC Asset Management Inc. bought a new stake in Insmed during the 3rd quarter valued at $133,000.

Insmed Stock Down 0.9 %

Shares of Insmed stock traded down $0.64 during midday trading on Tuesday, hitting $68.29. The company had a trading volume of 2,871,810 shares, compared to its average volume of 2,076,551. The company has a 50 day moving average of $71.25 and a 200 day moving average of $72.47. The stock has a market capitalization of $12.22 billion, a P/E ratio of -12.30 and a beta of 1.12. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. The business's quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.10) EPS. On average, equities analysts predict that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

INSM has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Bank of America boosted their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. JPMorgan Chase & Co. raised their price objective on shares of Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a report on Friday, November 22nd. Finally, Truist Financial reaffirmed a "buy" rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insmed currently has an average rating of "Moderate Buy" and an average price target of $83.67.

Insiders Place Their Bets

In other Insmed news, COO Roger Adsett sold 4,902 shares of the business's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.68, for a total transaction of $312,159.36. Following the completion of the sale, the chief operating officer now owns 147,539 shares of the company's stock, valued at approximately $9,395,283.52. The trade was a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the completion of the sale, the chief executive officer now directly owns 384,960 shares of the company's stock, valued at $26,912,553.60. This represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 70,094 shares of company stock valued at $4,733,986. Company insiders own 4.60% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.